Introduction
Interleukin (1L)-4 and IL-13 are two related cytokines with overlapping but not identical biological properties. Both inhibit production of proinflammatory cytokines and chemokines by monocytes [1, 2] and both induce the same morphological changes and increase expression of vascular cell adhesion molecule 1 on endothelial cells [3, 4] . Human B-cell responses to IL-4 and IL-13 are also very similar. Activation by either cytokine results in increased surface expression of CD23 and IgM whereas co-stimulation with anti-IgM or CD40 monoclonal antibody induces B-cell proliferation [5-71. In addition, IgE secretion is obtained by co-stimulation with CD40 monoclonal antibodies or recombinant CD40L 161. Although the responses of human B-cells to IL-4 and IL-13 are qualitatively the same, the responses to IL-13 are generally Abbreviations used: IL, interleukin; IL-4R, IL-4 receptor; IL-l3R, IL-13 receptor; DNlllr fibronectin type 111; X-SCID, X-linked severe combined immunodeficiency.
smaller than those to IL-4. In addition, IL-4 is active on T-cells and murine B-cells whereas IL-13 is not [Z] .
Receptors for IL-4 and IL-I 3
T h e very similar biological activities of IL-4 and IL-13 on many cell types suggests that these two cytokines share a common receptor or receptor component. T h e IL-4 receptor (IL-4R) is a heterodimeric complex consisting of the IL-4Ra-chain (p140), which binds IL-4, and the common y-chain (yc-chain), which is also shared by the receptors for IL-2, IL-7, IL-9 and IL-15 [8, 9] . IL-13 does not bind to the IL-4Ra-chain or to the IL-4RoJyc complex [lo] , but there is now good evidence that the IL-4Ra-chain is a nonbinding component of the IL-13 receptor (IL-13R) [ll] . This conclusion is based on experiments with the IL-4 mutant protein IL-+r1241) in which the tyrosine residue at position 124 is replaced with aspartic acid, and with blocking antibodies specific for the IL-4Ra-chain. T h e mutant IL-+.,.124D binds to the IL-4Ra-chain with approximately the same affinity as wild-type IL-4 but is unable to signal because of the amino acid substitution in the site required for interaction with the yc-chain [12-141. T h e fact that IL-$124D inhibits responses to both IL-4 and IL-13 implicates the IL-4Ra-chain as a component of the receptors for both cytokines. This conclusion is supported by experiments showing that monoclonal antibody to IL-4Ra-chain also inhibits responses to 16] .
In the past year, human and murine IL-13Rs have been cloned [17, 18] . T h e human IL-13R is a 354-amino acid type-I membrane glycoprotein belonging to the cytokine receptor superfamily [ 171. It has an extracellular segment consisting of a distal immunoglobulin-like domain followed by a cytokine receptor domain with four conserved cysteine residues and a proximal fibronectin type-I11 (FNIII) domain with the conserved WSXWS motif characteristic of these receptors ( Figure 1 ). T h e transmembrane domain is followed by a short intracellular segment of only 17 amino acids. The mouse IL-13R is similar, with an extracellular immunoglobulinlike domain followed by a cytokine receptor domain and an FNlll domain. T h e cytoplasmic segment is longer than in the human receptor, however, with 60 amino acids [18] . Both chains have been shown to associate with the IL-4Ra-chain to form a receptor that binds both IL-4 and IL-13. CTLLZ cells expressing the IL-13R-IL-4Ra complex respond weakly to IL-13, but Ba/F3 B-cells transfected with both chains are unable to respond to IL-13, suggesting further complexity. Interestingly, there is little sequence similarity between the human and mouse IL-13R and it is possible that the receptor complex may exist in different forms.
A minimal model showing the relationship between the receptors for IL-4 and IL-13 is shown in Figure 2 . T h e possibility that there are two IL-13R proteins and the evidence for another low-affinity receptor for IL-4 that is not related to any of these structures [ 191 adds further complexity to this model that has not yet been elucidated.
Signalling
IL-4 seems to activate two signalling pathways consistent with coupling to two IL-4Rs. High concentrations of IL-4 activate a unique signaltransduction pathway in human B-cells characterized by rapid and transitory hydrolysis of phosphatidylinositol bisphosphate and Ca2+ mobilization followed after a short lag period by an increase in cytoplasmic CAMP [ZO] . This pathway is also activated in human monocytes by IL-13 [Zl], and we have found that IL-13 stimulates inositol trisphosphate production and a delayed increase in intracellular CAMP in human B-cells (L. M. Hibbert and R. E. Callard, unpublished work). On the other hand, IL-4 binding to the high-affinity IL-4Rdyc activates protein tyrosine kinases including Jakl and Jak3 with phos- [35, 36] . In a recent study from this laboratory, B-cells from patients with X-SCID were used as a naturally occurring gene-inactivation model to examine the biological role of the yc-chain in B-cell responses to IL-2, IL-4, IL-13 and IL-15 [37] . As expected, these B-cells were unable to respond to IL-2 or IL-15, consistent with the yc-chain being a functional component of the receptors for both these cytokines [38, 39] . In contrast, IL-4 responses by these B-cells were normal in assays for B-cell activation (surface CD23 and IgM expression), proliferation on co-stimulation with anti-IgM or CD40 antibodies, and IgE production on co-stimulation with CD40 antibodies or CD40L. Detailed examination of X-SCID B-cell responses to showed that the absence of the yc-chain did not reduce their sensitivity to IL-4 [40] . X-SCID B-cell responses to IL-13 were also unaffected [37, 40] . These results show that the yc-chain is not required for B-cell responses to IL-4 and suggested that IL-4 could activate human B-cells through an alternative receptor other than the IL-4Rdyc complex. One possibility is that IL-4 acts through the IL-13R consisting of the IL-4Ra-chain complexed with the recently identified IL-13-binding proteins. X-SCID B-cell responses to IL-4 and IL-13 were inhibited by both IL-4R124D and a blocking IL-4Ra specific monoclonal antibody, showing that the IL-4Ra-chain is a component of the alternative IL-4R expressed on X-SCID B-cells. Formal proof that IL-4 activates B-cells through the IL-13R complex, however, awaits blocking experiments with IL-13 mutant proteins and/or IL-13R-specific monoclonal antibodies.
453
yc-chain cytokine receptors preferentially co-stimulate with B-cell antigen receptor whereas non-yc-chain receptors preferentially co-stimulate with CD40
We have recently found that co-stimulation of human tonsillar or peripheral blood B-cells with CD40 antibody and IL-13 results in a significantly bigger proliferative response than costimulation with anti-IgM and IL-13 (D. J. Matthews and R. E. Callard, unpublished work) . Exactly the opposite is observed with IL-2, where co-stimulation with anti-IgM gives a bigger response than co-stimulation with CD40 antibody. This reciprocal effect suggests that the B-cell receptor signalling (anti-IgM) preferentially co-stimulates with cytokine receptors that include the yc-chain, whereas CD40 preferentially co-stimulates with receptors that do not include the yc-chain, for example the IL-13R complex. T h e comparable proliferative responses obtained by IL-4 co-stimulation with anti-IgM and CD40 are consistent with IL-4 activation of B-cells through both IL-4Rdyc and IL-4Ra-IL-13R complexes. In contrast, responses of X-SCID B-cells to IL-4 and CD40 are greater than to IL-4 and anti-IgM because, in this model, IL-4 acts only through the IL-13R complex.
Functional implications of two IL-4Rs on B-cells
T h e expression of two IL-4Rs on normal B-cells has significant functional implications. High-and low-affinity IL-4Rs on human lymphocytes were shown some time ago by Scatchard plots from conventional binding studies [41] . Evidence for two IL-4Rs was also obtained from experiments showing that 50 times higher concentrations of IL-4 are required for optimal CD23 expression than soluble IgM expression by human B-cells [42] . These differences are unlikely to be due to IL-4 interaction with IL-4Rdyc and IL-4Ra-IL-13R complexes for two reasons. First, expression of both CD23 and soluble IgM is increased by IL-13 and IL-4, and second the yc-chain is responsible for only a small increase in affinity of the IL-4Ra-chain for IL-4, and the affinity of the IL-4Ra-IL-13R complex is similar to the affinity of the IL-4Rdyc complex for IL-4 [9, 43] . The difference may be due instead to the existence of a low-affinity IL-4R, which has been described previously but not cloned [19] .
In other experiments, low doses of IL-4 were found to enhance secretion of IgM, IgG and IgA but not IgE by Epstein-Barr virus-activated B-cells, whereas high doses of IL-4 induced secretion of IgE and IgG4 but not the other isotypes [44] . In similar experiments with IL-13, only IgE secretion was obtained. IL-13 was unable to increase secretion of IgM, IgG or IgA at any concentration (K. Kotowicz and R. E. Callard, unpublished work) . These experiments suggest that the effect of IL-4 on IgM, IgG and IgA was mediated by the IL-4Rdyc complex whereas the production of IgE depended on IL-4 or IL-13 activation of the IL-4Ra-IL-13R complex. The possibility that IgE production depends on signalling through the IL-13R complex has major implications for our understanding of the role of IL-4 in allergy and for the development of mutant IL-4 (or IL-13) proteins as receptor antagonists for the treatment of diseases associated with type-2 immunity.
